## Epiyangambin

MedChemExpress

Cat. No.:	HY-121377	
CAS No.:	24192-64-1	
Molecular Formula:	C <sub>24</sub> H <sub>30</sub> O <sub>8</sub>	
Molecular Weight:	446.49	
Target:	Platelet-activating Factor Receptor (PAFR)	
Pathway:	GPCR/G Protein	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	`0~{

BIOLOGICAL ACTIVITY				
Description	Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF- induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells) <sup>[1][2]</sup> .			
In Vitro	Epiyangambin (0-25 μM; 24 h) inhibits growth of SW480 cells in a dose-dependent manner <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay <sup>[1]</sup>			
	Cell Line:	SW480 cells		
	Concentration:	0-25 μΜ		
	Incubation Time:	24 h		
	Result:	Caused reductions in cell number in a dose-dependent manner.		
In Vivo	Epiyangambin (20 mg/kg) significantly inhibits PAF (platelet activating factor)-induced thrombocytopenia in rats <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

## REFERENCES

[1]. Hausott B, et al. Naturally occurring lignans efficiently induce apoptosis in colorectal tumor cells. J Cancer Res Clin Oncol. 2003 Oct;129(10):569-76.

[2]. Castro-Faria-Neto HC, et al. Pharmacological profile of epiyangambin: a furofuran lignan with PAF antagonist activity. J Lipid Mediat. 1993 May;7(1):1-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fa

Fax: 609-228-5909

09 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA